Dr. Siqing FU, MD
Claim this profileMD Anderson Cancer Center
About Siqing FU, MD
Education:
- Graduated from Tongji Medical University.
- Completed Residency in Internal Medicine at the University of Rochester.
- Undertook Fellowship in Hematology and Medical Oncology at the University of Rochester.
Experience:
- Served an Internship in Internal Medicine at Yale-New Haven Medical Center.
- Specializes in treating lung cancer, small intestine cancer, and chronic anemia.
- Over 21 years of practice at the University of Texas MD Anderson Cancer Center.
- Certified by the American Board of Internal Medicine in Medical Oncology.
- Holds active medical licenses in multiple states, including Texas, New York, and California.
Area of expertise
Cancer
Siqing FU, MD has run 15 trials for Cancer. Some of their research focus areas include:
Solid Tumors
Siqing FU, MD has run 12 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
The University Of Texas M.D. Anderson Cancer Center
Clinical Trials Siqing FU, MD is currently running
CBP-1019 Combinations
for Cancer
An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.
Recruiting
1 award
Phase 1
5 criteria
TSN1611
for Cancer
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.
Recruiting
1 award
Phase 1 & 2
3 criteria
More about Siqing FU, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 28 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Siqing FU, MD has experience with
- Pembrolizumab
- Bevacizumab
- CBP-1019
- Oxaliplatin
- Tumor Treating Fields Therapy
- Fluorouracil
Breakdown of trials Siqing FU, MD has run
Solid Tumors
Pancreatic Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Siqing FU, MD specialize in?
Siqing FU, MD focuses on Cancer and Solid Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are metastatic.
Is Siqing FU, MD currently recruiting for clinical trials?
Yes, Siqing FU, MD is currently recruiting for 8 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Siqing FU, MD has studied deeply?
Yes, Siqing FU, MD has studied treatments such as Pembrolizumab, Bevacizumab, CBP-1019.
What is the best way to schedule an appointment with Siqing FU, MD?
Apply for one of the trials that Siqing FU, MD is conducting.
What is the office address of Siqing FU, MD?
The office of Siqing FU, MD is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.